What is Phacilitate’s SIG?

What exactly is this event about?

  • A select group delivering a roadmap to cost-effective, robust and interconnected ‘vein to vein’ manufacturing and supply chain models
  • A highly immersive blend of intense brainstorming sessions and innovative, activity-based networking in an exclusive location geared to optimising interaction
  • The source of a variety of invaluable, tangible ‘take-homes’ variously defining for participants and their organisations:
    • the technical state-of-the-art in automation today
    • the affordability and ROI from automation at each stage of cell & gene therapy R&D/commercialisation
  • The only event to specifically examine automation relating to product characterisation, quality testing, raw/starting materials and logistics tools and processes, in addition to bioprocessing systems
  • A ‘landing point’ in cell & gene therapy for leading bioengineers from the fringes of the sector
  • An opportunity for each and every attendee to bring a specific issue or challenge to the table for discussion by the group
  • The perfect setting to develop genuinely valuable and lasting new contacts


What you could gain from from participation?

  • Establish your tools and services as a key component in the vein-to-vein models of the future (be part of the ONLY directory for automated cell and gene therapy solutions)
  • Demonstrate the ROI for automation in cell and gene therapy
  • Show technicians how to integrate your solution into their workflow
  • 2 birds, 1 stone: demonstrate to the do-ers, strategize with their Win the race: Meet biotechs BEFORE they execute their automation strategy
  • Have your voice heard: Be a part of a peer-reviewed automation manifesto
  • Directly influence the technological decisions and strategic agenda through  invitationonly focus groups
  • Create a feedback loop: Run a user group meeting and improve your products


Steering committee

  • Dr Stefano Baila, Process Development Manager, Celyad
  • Dr Dolores Baksch, Innovation Leader, Cell Therapy Technologies, GE Healthcare
  • David Brindley, DPhil, MEng, FRSA, Senior Research Fellow in Healthcare Translation, Department of Paediatrics, University of Oxford
  • Kim Bure, Director, Regenerative Medicine, Sartorius Stedim Biotech
  • Professor John Campbell, Associate Director, Research, Development & Innovation, Scottish National Blood Transfusion Service (SNBTS)

View the full list here